Core Viewpoint - The company, Dahongli (300865.SZ), focuses on the research, development, production, and sales of complete sets of equipment for sand and stone, as well as mining crushing and screening [1] Group 1: Business Overview - The main business of the company includes the development, production, and sales of integrated environmental protection intelligent crushing production equipment and overall solutions [1] - The company's products are widely used in infrastructure projects such as transportation, housing construction, urban public construction, and water conservancy and hydropower [1]

Core Points - The Shanghai Composite Index closed at 3956.72 points, slightly below the five-day moving average, with a change of 0.05% [1] - The total trading volume of A-shares reached 1,398.50 billion yuan [1] - A total of 737 A-shares have prices that surpassed the five-day moving average, indicating market activity [1] Summary of Stocks with Significant Deviation from the Five-Day Moving Average - Baose shares (300402) had the highest deviation at 14.65%, with a price increase of 19.99% and a turnover rate of 3.61% [2] - Guorui Technology (300600) followed with a deviation of 8.16%, a price increase of 12.10%, and a turnover rate of 12.34% [2] - Guoji General (600444) recorded a deviation of 7.91%, with a price increase of 10.02% and a turnover rate of 7.80% [2] - Other notable stocks include Intercontinental Oil & Gas (600759) with a 7.85% deviation and Donghua Technology (002140) with a 7.27% deviation [2] - The table lists various stocks with their respective price changes, turnover rates, five-day moving averages, latest prices, and deviation percentages [2]

Core Viewpoint - The company ensures the authenticity, accuracy, and completeness of its quarterly report, with all board members and senior management bearing legal responsibility for any misrepresentation or omissions [2]. Financial Data Summary - The third-quarter financial report has not been audited [7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. - The company has not reclassified any non-recurring profit and loss items as recurring [3]. Changes in Financial Indicators - The company has provided explanations for changes in the balance sheet, income statement, and cash flow statement, although specific figures are not detailed in the provided documents [4][5].

Core Points - Dahongli announced a comprehensive review of assets that may show signs of impairment for the period from January to September 2025, including receivables, prepayments, other receivables, contract assets, inventory, fixed assets, construction in progress, long-term equity investments, and intangible assets [1] - The company has recognized an asset impairment provision amounting to 3,032,288.57 yuan for the same period [1]

大宏立(300865.SZ)发布2025年三季度报告，该公司前三季度营业收入为2.43亿元，同比减少19.50%。归 属于上市公司股东的净利润为1042.12万元，同比减少44.69%。归属于上市公司股东的扣除非经常性损 益的净利润为501.34万元，同比减少65.79%。基本每股收益为0.1089元。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司 2024 年限制性股票激励计划已履行的相关审批程序 1、2024 年 9 月 29 日，公司召开第四届董事会第二十八次会议和第四届监 事会第二十三次会议，审议通过了《关于公司<2024 年限制性股票激励计划（草 案）>及其摘要的议案》《关于公司<2024 年限制性股票激励计划实施考核管理 办法>的议案》等议案，律师事务所出具法律意见书。 2、2024 年 10 月 1 日至 2024 年 10 月 10 日，公司对本激励计划激励对象名 单与职务在公司内部进行了公示，在公示期内，监事会未收到个人或组织提出的 针对本次激励计划激励对象名单人员的异议，并于 2024 年 10 月 11 日披露了《监 事会关于 2024 年限制性股票激励计划首次授予激励对象名单的核查意见及公示 情况说明》。 3、2024 年 10 月 16 日，公司召开 2024 年第三次临时股东大会，审议通过 了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2024 年限制性股票激励计划实施考核管理办法> ...

Group 1 - The core point of the article is that Dahongli (SZ 300865) held its third meeting of the fifth board of directors on October 23, 2025, to discuss the proposal for the reappointment of the accounting firm for the 2025 fiscal year [1] - For the fiscal year 2024, Dahongli's revenue composition is 98.51% from the mining machinery manufacturing industry and 1.49% from other businesses [1] - As of the report date, Dahongli has a market capitalization of 3.2 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting a hot secondary market in biomedicine [1] - There is a discussion on why the primary market is experiencing a fundraising slowdown despite the active secondary market [1]

（记者 王晓波） 截至发稿，大宏立市值为32亿元。 每经头条（nbdtoutiao）——中国创新药，今年海外授权已卖出800亿美元！对话创东方投资合伙人卢 刚：生物医药二级市场火热，一级市场为何募资遇冷？ 每经AI快讯，大宏立（SZ 300865，收盘价：33.1元）10月24日晚间发布三季度业绩公告称，2025年前 三季度营收约2.43亿元，同比减少19.5%；归属于上市公司股东的净利润约1042万元，同比减少 44.69%；基本每股收益0.1089元，同比减少44.69%。 ...

Core Insights - The company reported a significant decline in revenue and net profit for the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The operating revenue for the third quarter was 62.82 million, representing a year-on-year decrease of 40.69% [1] - The net profit attributable to shareholders was 1.40 million, showing a year-on-year decline of 82.07% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -1.34 million, indicating a loss [1]

国都证券股份有限公司关于成都大宏立机器股份有限公司使用部分超募资金永久补充流动资金的核查意见 国都证券股份有限公司 关于成都大宏立机器股份有限公司 使用部分超募资金永久补充流动资金的核查意见 国都证券股份有限公司（以下简称"国都证券"或"保荐机构"）作为成都大 宏立机器股份有限公司（以下简称"大宏立"或"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司募 集资金监管规则》及修订说明、《深圳证券交易所创业板股票上市规则（2025 年修订）》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规 范运作（2025 年修订）》及发布通知、《深圳证券交易所上市公司自律监管指引 第 13 号—保荐业务》等有关法律、法规和规范性文件的要求，对大宏立使用部 分超募资金永久补充流动资金进行了审慎的核查，并出具核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会"证监许可[2020]1578 号"文《关于同意成都大 宏立机器股份有限公司首次公开发行股票注册的批复》的许可，大宏立首次公 开发行人民币普通股（A 股）2,392.00 万股（每股面值 1 元） ...